Publications by authors named "Shannon Schneider"
Article Synopsis
- Moderate-to-severe atopic dermatitis (AD) significantly affects patients' quality of life, and advanced systemic therapeutics (AST) like dupilumab and upadacitinib are available but underutilized.
- A study of 3,076 patients in the U.S. found that 436 were eligible for AST treatment, and factors like private insurance and disease severity influenced their treatment initiation.
- Despite the availability of AST, many patients—47% of adolescents and 58% of adults—remain untreated, highlighting a need for greater advocacy and accessibility for those with severe AD.
Article Synopsis
- The study aimed to evaluate the effects of tralokinumab, a treatment for chronic moderate-to-severe atopic dermatitis, compared to a placebo on various clinically important outcomes in patients not reaching the main goal of clear skin at week 16.
- A total of 1328 patients from two phase III trials, ECZTRA 1 and 2, were analyzed, focusing on improvements in eczema severity and patient-reported symptoms like itch and quality of life.
- Results showed that significantly more patients using tralokinumab attained meaningful improvements in eczema severity (EASI-50), itch ratings, and quality of life compared to those on placebo, indicating tralokinumab's potential benefits beyond just achieving clear skin.
Importance: Older adults with atopic dermatitis (AD) face unique treatment challenges, including comorbidities, polypharmacy, and a higher risk for infections (eg, herpes zoster). Furthermore, limited data are available from clinical trials for treatments in this population. In phase 3 studies, tralokinumab showed superior efficacy in moderate-to-severe AD vs placebo, but results were not stratified by age group.
View Article and Find Full Text PDFArticle Synopsis
- * Tralokinumab is a new monoclonal antibody that targets IL-13, showing significant improvements in AD symptoms in three phase 3 clinical trials, both alone and with topical corticosteroids.
- * Treatment with tralokinumab leads to noticeable symptom relief, including reduced itch and better sleep, while maintaining a safety profile similar to a placebo, making it a strong new option for managing moderate-to-severe AD.
Introduction: In pivotal phase 3 tralokinumab monotherapy (ECZTRA 1/2) and topical corticosteroid (TCS) combination (ECZTRA 3) trials in adults with moderate-to-severe atopic dermatitis (AD), tralokinumab significantly improved signs and symptoms of AD. Geographic region may impact treatment response due to potential differences in race and ethnicity, and based on findings in other therapy areas. Here, we evaluated the efficacy and safety of tralokinumab in the ECZTRA 1/2/3 North American population at week 16, as well as maintenance of responses over time, and compared these data side-by-side with those of the ECZTRA 1/2/3 non-North American population.
View Article and Find Full Text PDFBackground: Tralokinumab, as monotherapy or in combination with topical corticosteroids (TCS), has exhibited marked efficacy through 52 weeks in phase 3 trials of adults with moderate-to-severe atopic dermatitis and additional efficacy in a long-term extension trial. Early changes in patient-reported symptoms have not been communicated.
Objective: To evaluate early changes in patient-reported outcomes (PROs) across the ECZTRA 1, 2, and 3 tralokinumab trials.